Company news

PolyPid Ltd. news in 2026

PolyPid Ltd.'s news releases, calls and decks from 2026, newest first.

View company

PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026

October 29, 2026

PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections

October 28, 2026

PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026

October 21, 2026

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

October 15, 2026

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

October 1, 2026

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

October 1, 2026

PolyPid Announces Participation in Upcoming Fall Investor Conferences

September 15, 2026

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 12, 2026

PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)

July 30, 2026

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

July 30, 2026

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

July 29, 2026

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

July 21, 2026

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

June 1, 2026

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

May 20, 2026

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 13, 2026

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

May 6, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

April 28, 2026

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

April 13, 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

March 30, 2026

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application

March 17, 2026

PolyPid Announces Participation in Upcoming Investor Conferences

February 25, 2026

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

January 28, 2026

Calls in 2026

Decks in 2026